Program
Abiraterone Acetate
Also written as “Abiraterone acetate”, “Abiraterone” and “abiraterone acetate”.
Its studies are mostly in Prostatic Neoplasms · Neoplasm Metastasis · Breast Neoplasms · Bulbo-Spinal Atrophy, X-Linked · Prostatic Neoplasms, Castration-Resistant, led by 8 companies.
Drug pageAbiraterone Acetate: every studyMany companies study it; this page follows only the 53 they lead. All 127 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnsonits history only | 414 open or running | phase 4since Mar 27, 2015 | May 11, 2007 | none ahead |
| Jiangsu HengRui Medicineits history only | 32 open or running | phase 2since Apr 25, 2021 | Apr 25, 2021 | Dec 2026phase 2 · NCT06568094 |
| Sun Pharmaceutical Industriesits history only | 31 open or running | phase 2since Mar 25, 2016 | Mar 25, 2016 | Dec 31, 2027phase 2 · NCT05422911 |
| Sanofiits history only | 20 open or running | phase 4since Jun 26, 2015 | Jan 4, 2012 | none ahead |
| Boryung Pharmaceuticalits history only | 10 open or running | phase 1since May 12, 2021 | May 12, 2021 | none ahead |
| Sino Biopharmaceuticalits history only | 10 open or running | phase 3since Aug 11, 2019 | Aug 11, 2019 | none ahead |
| Sumitomo Pharma | 10 open or running | phase 1since Dec 7, 2020 | Dec 7, 2020 | none ahead |
| Zentiva, k.s.its history only | 10 open or running | phase 1since Mar 2, 2020 | Mar 2, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sumitomo Pharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 7, 2020First study: phase 1 study in Metastatic Castration-Resistant Prostate CancerFirst studyNCT04666129 · 48 enrolled · United States
TargetBeta
“Cytochrome P450 17A1 inhibitor”ChEMBL 37, by rule
Studies
The one study Sumitomo Pharma leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04666129Metastatic Castration-Resistant Prostate Cancer · United States | 1 | Completed | May 28, 2024 | 48 |
How it is read
Names in the registry
- “Abiraterone acetate”, 24 entries
- “Abiraterone”, 10 entries
- “Abiraterone Acetate”, 5 entries
- “abiraterone acetate”, 2 entries
- “Abiraterone acetate (Treatment B)”, 2 entries
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 43 studies
- Neoplasm Metastasis, 2 studies
- Breast Neoplasms, 2 studies
- Bulbo-Spinal Atrophy, X-Linked, 1 study
- Prostatic Neoplasms, Castration-Resistant, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.